Projected Annual Revenue
$9,274,290
Year 2 steady state
EBITDA Margin
88.85%
Operating profitability
Payback Period
1 months
Time to profitability
Valuation Estimate
$52,189,740
6x EBITDA multiple
Revenue Assumptions
50
10200
5.0%
0.0%20.0%
$2500
$1500$4000
Cost Structure
$25000
$10000$60000
$8000
$3000$20000
$10000
$2000$30000
Procedure Mix
2.5
1.05.0
3.0
1.06.0
$400
$200$800
Investment Highlights
Market Opportunity
- Large addressable market with 25% of population affected by venous disease
- Growing demand for minimally invasive vein treatments
- Favorable reimbursement landscape from commercial payers
Financial Strengths
- High-margin procedures with strong unit economics
- Predictable recurring revenue from established referral networks
- Capital-efficient model with rapid payback period
Key Metrics Summary
Annual Revenue
$9,274,290
EBITDA
$8,240,207
Margin
88.85%
Valuation
$52,189,740
Note on Valuation
Valuation estimate is based on a 6x EBITDA multiple, which is typical for healthcare service businesses. Actual valuation may vary based on market conditions, growth trajectory, and competitive positioning.